The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Use of the Thyroid Hormone Analogue Eprotirome in Statin-Treated Dyslipidemia
Open accessAbstract
BACKGROUND: Dyslipidemia increases the risk of atherosclerotic cardiovascular disease and is incompletely reversed by statin therapy alone in many patients. Thyroid hormone lowers levels of serum low-density lipoprotein (LDL) cholesterol and has other potentially favorable actions on lipoprotein metabolism. Consequently, thyromimetic drugs hold promise as lipid-lowering agents if adverse effects can be avoided. METHODS: We performed a randomized, placebo-controlled, double-blind, multicenter trial to assess the safety and efficacy of the thyromimetic compound eprotirome (KB2115) in lowering the level of serum LDL cholesterol in patients with hypercholesterolemia who were already receiving simvastatin or atorvastatin. In addition to statin treatment, patients received either eprotirome (at a dose of 25, 50, or 100 microg per day) or placebo. Secondary outcomes were changes in levels of serum apolipoprotein B, triglycerides, and Lp(a) lipoprotein. Patients were monitored for potential adverse thyromimetic effects on the heart, bone, and pituitary. RESULTS: The addition of placebo or eprotirome at a dose of 25, 50, or 100 microg daily to statin treatment for 12 weeks reduced the mean level of serum LDL cholesterol from 141 mg per deciliter (3.6 mmol per liter) to 127, 113, 99, and 94 mg per deciliter (3.3, 2.9, 2.6, and 2.4 mmol per liter), respectively, (mean reduction from baseline, 7%, 22%, 28%, and 32%). Similar reductions were seen in levels of serum apolipoprotein B, triglycerides, and Lp(a) lipoprotein. Eprotirome therapy was not associated with adverse effects on the heart or bone. No change in levels of serum thyrotropin or triiodothyronine was detected, although the thyroxine level decreased in patients receiving eprotirome. CONCLUSIONS: In this 12-week trial, the thyroid hormone analogue eprotirome was associated with decreases in levels of atherogenic lipoproteins in patients receiving treatment with statins. (ClinicalTrials.gov number, NCT00593047.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
A DISTRIBUTION-FREE k-SAMPLE TEST AGAINST ORDERED ALTERNATIVES
JONCKHEERE, A. R. (1954) · Biometrika · doi:10.1093/biomet/41.1-2.133 · Cited by 1,500
Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408
Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
Kastelein, J. J. P., Akdim, F., Stroes, E. S. G., Zwinderman, A. H., Bots, M. L., Stalenhoef, A. F. H., Visseren, F. L. J., Sijbrands, E. J. G., Trip, M. D., Stein, E. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800742 · Cited by 1,241
ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins
Writing Committee Members:, Pasternak, R. C., Smith, S. C., Bairey-Merz, C. N., Grundy, S. M., Cleeman, J. I., & Lenfant, C. (2002) · Circulation · doi:10.1161/01.cir.0000032466.44170.44 · Cited by 1,088
Pearson, T. A., Laurora, I., Chu, H., & Kafonek, S. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.4.459 · Cited by 1,012
Extended-Release Niacin or Ezetimibe and Carotid Intima–Media Thickness
Taylor, A. J., Villines, T. C., Stanek, E. J., Devine, P. J., Griffen, L., Miller, M., Weissman, N. J., & Turco, M. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0907569 · Cited by 644
Bennet, A. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.6.598 · Cited by 281
Thompson, G. R., Soutar, A. K., Spengel, F. A., Jadhav, A., Gavigan, S. J., & Myant, N. B. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.4.2591 · Cited by 274
Brunzell, J. D. (2007) · New England Journal of Medicine · doi:10.1056/nejmcp070061 · Cited by 268
Plasma triglyceride metabolism in thyroid disease
Nikkilä, E. A., & Kekki, M. (1972) · Journal of Clinical Investigation · doi:10.1172/jci107017 · Cited by 242
WALTON, K. W., Scott, P., Dykes, P. W., & Davies, J. W. L. (1965) · PubMed · Cited by 241
Grover, G. J., Mellström, K., Ye, L., Malm, J., Li, Y.-L., Bladh, L.-G., Sleph, P. G., Smith, M. A., George, R., Vennström, B., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1633737100 · Cited by 222
Self-citationMaio, A., & Dowd, F. J. (2010) · xPharm: The Comprehensive Pharmacology Reference · doi:10.1016/b978-008055232-3.60628-2 · Cited by 209
Johansson, L., Rudling, M., Scanlan, T. S., Lundåsen, T., Webb, P., Baxter, J., Angelin, B., & Parini, P. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504379102 · Cited by 200
Self-citationGloss, B., Trost, S. U., Bluhm, W. F., Swanson, E. A., Clark, R., Winkfein, R., Janzen, K. M., Giles, W., Chassande, O., Samarut, J., et al. (2001) · Endocrinology · doi:10.1210/endo.142.2.7935 · Cited by 195
Berkenstam, A., Kristensen, J., Mellström, K., Carlsson, B., Malm, J., Rehnmark, S., Garg, N., Andersson, C. M., Rudling, M., Sjöberg, F., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705286104 · Cited by 193
Self-citationBlood Cholesterol Values in Hyperthyroidism and Hypothyroidism — Their Significance
MASON, R. L., HUNT, H. M., & HURXTHAL, L. (1930) · New England Journal of Medicine · doi:10.1056/nejm193012252032601 · Cited by 166
Ness, G. C., Pendleton, L. C., Li, Y. C., & Chiang, J. Y. L. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(90)91568-d · Cited by 148
Requirement for Thyroid Hormone Receptor β in T3Regulation of Cholesterol Metabolism in Mice
Gullberg, H., Rudling, M. J., Saltó, C., Forrest, D., Angelin, B., & Vennström, B. (2002) · Molecular Endocrinology · doi:10.1210/me.2002-0009 · Cited by 132
Self-citationA thyromimetic that decreases plasma cholesterol levels without increasing cardiac activity
Underwood, A. H., Emmett, J. C., Ellis, D. A., Flynn, S. B., Leeson, P. D., Benson, G. M., Novelli, R., Pearce, N. J., & Shah, V. P. (1986) · Nature · doi:10.1038/324425a0 · Cited by 131
Goldman, S., McCarren, M., Morkin, E., Ladenson, P. W., Edson, R., Warren, S., Ohm, J., Thai, H., Churby, L., Barnhill, J., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.834424 · Cited by 117
Self-citationThyroid Hormone Regulates Type I Deiodinase Messenger RNA in Rat Liver
Berry, M. J., Kates, A., & Larsen, P. R. (1990) · Molecular Endocrinology · doi:10.1210/mend-4-5-743 · Cited by 117
Hashimoto, K., Yamada, M., Matsumoto, S., Monden, T., Satoh, T., & Mori, M. (2006) · Endocrinology · doi:10.1210/en.2006-0116 · Cited by 86
Augmented Hepatic and Skeletal Thyromimetic Effects of Tiratricol in Comparison with Levothyroxine
Sherman, S. I., Ringel, M. D., Smith, M. J., Kopelen, H. A., Zoghbi, W. A., & Ladenson, P. W. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.7.2153 · Cited by 75
Self-citationGälman, C., Bonde, Y., Matasconi, M., Angelin, B., & Rudling, M. J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.01.032 · Cited by 74
Self-citationLadenson, P. W., McCarren, M., Morkin, E., Edson, R., Shih, M., Warren, S., BARNHILL, J. G., Churby, L., Thai, H. M., O’Brien, T., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1209 · Cited by 57
Self-citationDAY, R., Gebhard, R. L., Schwartz, H. L., Strait, K. A., DUANE, W. C., Stone, B. G., & Oppenheimer, J. H. (1989) · Endocrinology · doi:10.1210/endo-125-1-459 · Cited by 56
Gloss, B. R. (2001) · Endocrinology · doi:10.1210/en.142.2.544 · Cited by 49
The coronary drug project--findings with regard to estrogen, dextrothyroxine, clofibrate and niacin.
Stamler, J. (1977) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4613-4220-5_6 · Cited by 46
Morkin, E., Pennock, G. D., Spooner, P. H., Bahl, J. J., Fox, K. U., & Goldman, S. (2002) · Cardiology · doi:10.1159/000063110 · Cited by 42
The Separate Hypolipoproteinemic Effects of Dextrothyroxine and Ethyl Chlorophenoxyisobutyrate
Strisower, E. H., & Strisower, B. (1964) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-24-2-139 · Cited by 33
EFFECTS OF HYPERTHYROIDISM ON BINDING PROTEINS FOR STEROID HORMONES
Caron, P., Bennet, A., Barousse, C., Nisula, B. C., & Louvet, J. (1989) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1989.tb01245.x · Cited by 14
Brudi, P., Reckless, J. P. D., Henry, D., Pomykaj, T., Lim, S. T., Massaad, R., Vandormael, K., & Johnson‐Levonas, A. O. (2008) · Cardiology · doi:10.1159/000172795 · Cited by 6
Cited by
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Thyroid Hormone Regulation of Metabolism
Mullur, R., Liu, Y.-Y., & Brent, G. A. (2014) · Physiological Reviews · doi:10.1152/physrev.00030.2013 · Cited by 2,421
Jonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., et al. (2014) · Thyroid® · doi:10.1089/thy.2014.0028 · Cited by 1,928
“Eprotirome therapy was associated with decreases in serum LDL, apolipoprotein B, triglycerides, and Lp(a) lipoprotein when added to statin therapy (668) and given as single therapy in primary hypercholesterolemia (670).”
Lipoprotein(a) as a cardiovascular risk factor: current status
Nordestgaard, B. G., Chapman, M. J., Ray, K., Borén, J., Andreotti, F., Watts, G. F., Ginsberg, H., Amarenco, P., Catapano, A., Descamps, O. S., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq386 · Cited by 1,807
Metadata
- Authors
- Ladenson, P. W., Kristensen, J. D., Ridgway, E. C., Olsson, A. G., Carlsson, B., Klein, I., Baxter, J. D., & Angelin, B.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-03-11
- Volume
- 362
- Issue
- 10
- Pages
- 906-916
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2097478986
- Cited by
- 338
- References
- 37
- FWCI
- 40.99
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.